



(B)

IFCN

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q58513

Ryuji UENO, et al.

Allowed: June 1, 2006

Appln. No.: 09/816,655

Group Art Unit: 1618

Confirmation No.: 5746

Examiner: Zohreh A. FAY

Filed: March 26, 2001

For: APOPTOSIS INHIBITOR

STATEMENT OF SUBSTANCE OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks summarizing the interview conducted on May 25, 2006:

REMARKS

An Examiner's Interview Summary Record (PTO-413) was attached with the Notice of Allowance dated June 1, 2006.

During the interview, the following was discussed:

1. Brief description of exhibits or demonstration: No.
2. Identification of claims discussed: 41 and 43.
3. Identification of art discussed: None.
4. Results of Interview: Agreement with respect tot the claims was reached.

Applicant authorized the amendments set forth in the examiner's amendment.


STATEMENT OF SUBSTANCE OF INTERVIEW
U.S. Application No. 09/816,655

Attorney Docket No. Q58513

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF
INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

It is believed that no petition or fee is required. However, if the USPTO deems
otherwise, Applicant hereby petitions for any extension of time which may be required to
maintain the pendency of this case, and any required fee, except for the Issue Fee, for such
extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,


Bruce E. Kramer
Registration No. 33,725

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: June 7, 2006